Barclays Raises Hims & Hers Target After Novo Deal Clears
Barclays boosts its target on Hims & Hers Health as Novo Nordisk deal removes a key legal overhang, while Progyny see...
Which Investors Should Avoid Robo Advisors outlines situations where automated options may underperform. This intro highlights alternatives to consider.
28,175 articlesBarclays boosts its target on Hims & Hers Health as Novo Nordisk deal removes a key legal overhang, while Progyny see...
Oil prices surged this week as markets faced renewed supply worries. The piece outlines practical ways americans can ...
Chevron’s warning on global supply outages could stall U.S. economic momentum, as higher energy costs bite households...
Tokyo unveils a sweeping move in crypto policy: a flat 20% tax on gains and a gateway for ETFs, paired with legal rec...
AMD faces a high-stakes test as the AI buildout accelerates and competition intensifies. History warns advanced micro...
Kalshi launches LINKPERP, a CFTC-regulated Chainlink perpetual contract, coinciding with LINK ETF assets surpassing $...
Strive's CEO says recent STRC and SATA declines were driven by leverage-induced liquidations rather than weakening fu...
Accenture warns AI’s carbon footprint could rise 11-fold by 2030 as data centers multiply worldwide. The piece examin...
Fresh hints from Michael Saylor about a new Bitcoin move spark debate about MicroStrategy's next step for BTC exposur...
Asian aviation stocks plunge as tensions in the Middle East disrupt major air corridors and trigger flight cancellati...
Meta reports rising engineering output amid a larger headcount, fueling a split between efficiency and payroll. The m...
Two Kalshi veterans are raising up to $35 million for a new prediction-market VC fund called 5c(c) Capital, backed by...